Arbutus Biopharma
ABUS
ABUS
91 hedge funds and large institutions have $87.5M invested in Arbutus Biopharma in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
44% less call options, than puts
Call options by funds: $2.76M | Put options by funds: $4.95M
Holders
91
Holding in Top 10
–
Calls
$2.76M
Puts
$4.95M
Top Buyers
| 1 | +$11.3M | |
| 2 | +$3.33M | |
| 3 | +$2.74M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.28M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.78M |
Top Sellers
| 1 | -$3.35M | |
| 2 | -$2.54M | |
| 3 | -$1.77M | |
| 4 |
Millennium Management
New York
|
-$1.74M |
| 5 |
Two Sigma Investments
New York
|
-$1.56M |